An orally bioactive inhibitor of CCR9, CCX282, has been developed and was well tolerated with encouraging results in clinical trials for Crohn’s disease (40), but no studies in treatment of GVHD has been reported so far. The gene discussed is CCR9; the disease is graft versus host disease.